Grow Brian 4

What Happened Brian Grow, Chief Commercial Officer of Organogenesis Holdings, received equity awards on February 18, 2026 totaling 416,335 shares (234,375 RSUs + 48,330 performance shares + 133,630 RSU-related derivative award) at $0.00 per share. Separately, 11,768 shares were disposed of at $3.84 each to cover tax withholding, generating $45,189 in withholding value. The awards are grants (not open-market purchases) and the small disposition was for tax liability rather than a voluntary sale.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026.
• Awards: 234,375 RSUs (F1), 48,330 performance-settlement shares (F2), and 133,630 derivative award RSUs (A). All awards reported at $0.00 acquisition price.
• Withholding: 11,768 shares withheld/disposed at $3.84/share to satisfy tax obligations (total $45,189) — transaction code F.
• Shares owned after the transactions: not provided in the supplied filing details.
• Footnotes: F1 — RSUs vest in equal annual installments over four years beginning Feb 15, 2026. F2 — 48,330 shares issued upon vesting/settlement of a 2025 performance award. F3 notes an option vesting schedule (exercisable in equal annual installments over four years beginning Feb 15, 2026) referenced in the filing.
• Filing timeliness: filed two days after the transaction date (Feb 20, 2026), within the typical two-business-day Form 4 reporting window.

Context

• These were equity grants and a tax-withholding disposition; awards are not purchases and do not by themselves signal buying pressure.
• The withholding disposition is common when RSUs or performance shares vest — the company withholds shares to satisfy tax obligations rather than requiring a cash payment.
• For retail investors, grants indicate continued executive compensation alignment with shareholders but are routine; the only cash-related figure disclosed here is the $45,189 value of shares withheld for taxes.